{"entity":{"id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","aka":[],"tldr":"A phase 1/2 trial of EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide in mesothelioma, run by Beijing Biotech, now recruiting.","summary":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma is a phase 1/2 interventional study registered as NCT07510815 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide. Conditions listed: Malignant Pleural Mesotheliomas. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07510815","url":"https://clinicaltrials.gov/study/NCT07510815"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["eb-mf-car-nk-01","fludarabine","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07510815","phase":"1/2","setting":"A Phase 1/2, Open-Label, Nonrandomized, Biomarker-Guided Study of Locoregional Allogeneic Dual-Target Mesothelin (MSLN) / Fibroblast Activation Protein (FAP) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Recurrent, or Refractory Pleural or Peritoneal Mesothelioma","sponsor":"Beijing Biotech","enrolled":36,"outcomes":[]},"route":"/trials/nct07510815/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","route":"/drugs/eb-mf-car-nk-01/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}